ContraFect Corp (CFRX) Short Interest Down 46.6% in January

ContraFect Corp (NASDAQ:CFRX) was the recipient of a large decrease in short interest in January. As of January 31st, there was short interest totalling 493,405 shares, a decrease of 46.6% from the January 15th total of 923,895 shares. Currently, 0.8% of the company’s shares are short sold. Based on an average trading volume of 813,746 shares, the short-interest ratio is currently 0.6 days.

Shares of NASDAQ CFRX opened at $0.41 on Thursday. ContraFect has a 1-year low of $0.35 and a 1-year high of $2.93. The stock has a market cap of $32.96 million, a price-to-earnings ratio of -1.11 and a beta of -0.48.

Separately, ValuEngine upgraded ContraFect from a “hold” rating to a “buy” rating in a report on Tuesday, November 6th.

In related news, major shareholder Fosun Pharmaceutical Shanghai sold 600,000 shares of the stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $2.04, for a total transaction of $1,224,000.00. Following the transaction, the insider now owns 7,900,000 shares of the company’s stock, valued at approximately $16,116,000. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 6.70% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of CFRX. Trellus Management Company LLC increased its holdings in ContraFect by 88.8% during the 3rd quarter. Trellus Management Company LLC now owns 83,955 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 39,492 shares during the period. Northern Trust Corp increased its holdings in ContraFect by 46.5% during the 4th quarter. Northern Trust Corp now owns 114,131 shares of the biotechnology company’s stock worth $175,000 after purchasing an additional 36,239 shares during the period. JPMorgan Chase & Co. increased its holdings in ContraFect by 108.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 167,182 shares of the biotechnology company’s stock worth $346,000 after purchasing an additional 86,848 shares during the period. Renaissance Technologies LLC increased its holdings in ContraFect by 40.6% during the 2nd quarter. Renaissance Technologies LLC now owns 200,500 shares of the biotechnology company’s stock worth $443,000 after purchasing an additional 57,900 shares during the period. Finally, White Pine Capital LLC increased its holdings in ContraFect by 24.9% during the 4th quarter. White Pine Capital LLC now owns 294,730 shares of the biotechnology company’s stock worth $451,000 after purchasing an additional 58,725 shares during the period. Institutional investors own 56.06% of the company’s stock.

TRADEMARK VIOLATION WARNING: “ContraFect Corp (CFRX) Short Interest Down 46.6% in January” was published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.themarketsdaily.com/2019/02/14/contrafect-corp-cfrx-short-interest-down-46-6-in-january.html.

ContraFect Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Recommended Story: Understanding Stock Ratings

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply